Emmaus Life Sciences, Inc.
EMMA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EMMA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EMMA
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases, with its only FDA-approved product, Endari® (prescription-grade L-glutamine oral powder), for reducing acute complications of sickle cell disease.
Key risk: Insufficient operating capital
BioSniper Score
Based on 4 of 6 signals
Market Cap
$5.8M
Cash Runway
—
Lead Asset
endari (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for Emmaus Life Sciences, Inc..
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases, with its only FDA-approved product, Endari® (prescription-grade L-glutamine oral powder), for reducing acute complications of sickle cell disease.
- Emmaus is a commercial-stage biopharmaceutical company focused on rare and orphan diseases, with Endari® as its only FDA-approved product [sec_mda · as of 2025-08-14].
- As of June 30, 2026, the company reported cash and equivalents of $2.8 million, total revenue of $6.3 million, and net income of $1.3 million [sec].
- The company has a shareholders' equity deficit of -$63.6 million and total debt of $25.0 million as of June 30, 2026 [sec].
- Endari® is reimbursable by the Centers for Medicare and Medicaid Services, every state Medicaid program, and many commercial payors [sec_mda · as of 2026-08-14].
- In September 2023, Emmaus suspended most preclinical activities to focus on commercial expansion of Endari® in the U.S. and the MENA region [sec_mda · as of 2024-11-19].
What works
- Endari® is the company's only FDA-approved product and is reimbursable by Medicare, Medicaid, and many commercial payors, providing a revenue base [sec_mda · as of 2026-08-14].
- The company has agreements with leading distributors, physician group purchasing organizations, and pharmacy benefits managers, making Endari® available at retail and specialty pharmacies nationwide [sec_mda · as of 2026-08-14].
- Emmaus reported net income of $1.3 million for the six months ended June 30, 2026, compared to a net loss of $2.0 million in the prior year period [sec].
What to weigh
- As of June 30, 2026, the company had cash of $2.8 million and stated it does not have sufficient operating capital without raising additional capital [sec_mda · as of 2026-08-14].
- The company has a significant accumulated deficit, with shareholders' equity of -$63.6 million as of June 30, 2026 [sec].
- Emmaus has only one approved product (Endari®) and has suspended most preclinical activities, making it heavily dependent on Endari® sales for revenue [sec_mda · as of 2024-11-19].
- The company may continue to incur net losses for the foreseeable future until it can generate increased net revenues from Endari® sales [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Emmaus is a commercial-stage biopharmaceutical company focused on rare diseases with Endari® as its only FDA-approved product.
“We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases. Our only product, Endari® (prescription-grade L-glutamine oral powder) is approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease”
SEC MD&A · August 14, 2025
The company does not have sufficient operating capital without raising additional capital as of June 30, 2026.
“Based on our losses to date, current liabilities and anticipated future net revenues, operating expenses, debt repayment obligations, and cash and cash equivalents of $2.8 million as of June 30, 2026, we do not have sufficient operating capital for our business without raising additional capital.”
SEC MD&A · August 14, 2026
Endari® is reimbursable by Medicare, Medicaid, and many commercial payors.
“Endari® is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari® for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari® is also reimbursable by many commercial payors.”
SEC MD&A · August 14, 2026
The company suspended most preclinical activities in September 2023 to focus on commercial expansion.
“In September 2023, we suspended most preclinical activities related to our product candidates to focus on commercial expansion of Endari® in the U.S. and the MENA region.”
SEC MD&A · November 19, 2024
Risks & what to watch (4)›
Key risks
- Insufficient operating capital — As of June 30, 2026, the company does not have sufficient operating capital without raising additional capital [sec_mda · as of 2026-08-14].
- Dependence on single product — Emmaus relies solely on Endari® for revenue and has suspended most preclinical pipeline activities [sec_mda · as of 2024-11-19].
- Negative shareholders' equity — Shareholders' equity is -$63.6 million as of June 30, 2026, indicating accumulated deficits [sec].
- Uncertain future profitability — The company may continue to incur net losses until it can increase Endari® sales [sec_mda · as of 2026-08-14].
What to watch
- Ability to raise additional capital given cash of $2.8 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Trend in Endari® sales and revenue growth, as the company is dependent on this single product [sec_mda · as of 2026-08-14].
- Progress in commercial expansion in the U.S. and MENA region following suspension of preclinical activities [sec_mda · as of 2024-11-19].
- Debt repayment obligations and their impact on liquidity [sec_mda · as of 2026-08-14].
Sources: Catalysts · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Emmaus Life Sciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Emmaus Life Sciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $2M · Net income $1M · Debt/OCF 3.3×
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.1%
- Days to cover
- 0.5
- Shares short
- 41,217
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EMMA short interestFrequently asked questions
What is the AI investment thesis for Emmaus Life Sciences, Inc.?
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on rare and orphan diseases, with its only FDA-approved product, Endari® (prescription-grade L-glutamine oral powder), for reducing acute complications of sickle cell disease.
What is Emmaus Life Sciences, Inc.'s lead drug candidate?
Emmaus Life Sciences, Inc.'s most advanced tracked candidate is endari (Approved) for Sickle cell disease.
Who is the CEO of Emmaus Life Sciences, Inc.?
Mr. Willis C. Lee M.S. is the chief executive officer of Emmaus Life Sciences, Inc. (EMMA).
Where is Emmaus Life Sciences, Inc. headquartered?
Emmaus Life Sciences, Inc. (EMMA) is headquartered in Torrance, CA, United States.
What therapeutic areas does Emmaus Life Sciences, Inc. focus on?
Emmaus Life Sciences, Inc. develops therapies across Oncology, Rare Disease, Immunology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.